Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | SLC5A2 | P31639 | 16/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305988 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29534778 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29394990 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL29414951 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL152362 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL152361 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL153622 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL9949259 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL285303 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR | |
| SCHEMBL98837 | 1.00 | ATM (0.59) | ATMSLC5A2SLC5A1ALDH1A1TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085565-A1 | ANTIGEN-BINDING MOLECULES AND USES THEREOF | Metirra Pty Ltd (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4566621-A2 | DLL3/CD3 BINDING PROTEINS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025049591-A1 | ANTI-CXCR4 ANTIBODIES AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-3802598-B1 | DLL3/CD3 BINDING PROTEINS FOR CANCER TREATMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-02-12 | — | — | EP | disclosed |
| US-12173083-B2 | Multi-specific binding proteins for cancer treatment | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-24 | — | — | US | disclosed |
| US-20230049124-A1 | IMPROVED METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | BASF PLANT SCIENCE COMPANY GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20220251236-A1 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT | BOEHRINGER INGELHEIM INT (DE) | 2022-08-11 | — | — | US | disclosed |
| US-11332541-B2 | Multi-specific binding proteins for cancer treatment | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-17 | — | — | US | disclosed |